Canaccord Genuity Group Has Lowered Expectations for Omada Health (NASDAQ:OMDA) Stock Price

Omada Health (NASDAQ:OMDA) had its price objective reduced by investment analysts at Canaccord Genuity Group from $28.00 to $22.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 56.58% from the stock’s previous close.

Several other equities analysts have also recently weighed in on the company. Evercore lifted their target price on Omada Health from $27.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Wells Fargo & Company initiated coverage on shares of Omada Health in a report on Thursday, January 8th. They set an “equal weight” rating and a $17.00 price target for the company. BMO Capital Markets lowered their price objective on shares of Omada Health from $27.00 to $18.00 and set an “outperform” rating on the stock in a research report on Friday. Weiss Ratings reiterated a “sell (d)” rating on shares of Omada Health in a research report on Thursday, January 22nd. Finally, Morgan Stanley decreased their target price on shares of Omada Health from $32.00 to $30.00 and set an “overweight” rating for the company in a research note on Friday. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $22.90.

Omada Health Stock Up 3.3%

Shares of Omada Health stock opened at $14.05 on Friday. Omada Health has a 12 month low of $10.28 and a 12 month high of $28.40. The stock has a market cap of $813.61 million and a PE ratio of -56.20. The business has a fifty day simple moving average of $14.03 and a 200-day simple moving average of $18.67.

Omada Health (NASDAQ:OMDA) last posted its quarterly earnings results on Thursday, March 5th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.12. The business had revenue of $75.85 million for the quarter.

Insider Buying and Selling

In related news, CEO Sean P. Duffy sold 230,479 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $15.60, for a total value of $3,595,472.40. Following the transaction, the chief executive officer owned 126,644 shares in the company, valued at approximately $1,975,646.40. This represents a 64.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, President Wei-Li Shao sold 5,618 shares of Omada Health stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $16.13, for a total transaction of $90,618.34. Following the completion of the sale, the president owned 69,079 shares of the company’s stock, valued at $1,114,244.27. This trade represents a 7.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 276,893 shares of company stock worth $4,336,787 in the last 90 days.

Institutional Investors Weigh In On Omada Health

Several institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd acquired a new position in Omada Health during the fourth quarter worth $297,000. Utah Retirement Systems acquired a new stake in shares of Omada Health in the fourth quarter worth about $1,237,000. VARCOV Co. bought a new stake in shares of Omada Health during the 4th quarter worth about $504,000. Voloridge Investment Management LLC acquired a new position in shares of Omada Health during the 4th quarter valued at about $2,590,000. Finally, Tudor Investment Corp ET AL increased its holdings in shares of Omada Health by 373.7% during the 4th quarter. Tudor Investment Corp ET AL now owns 211,416 shares of the company’s stock valued at $3,336,000 after acquiring an additional 166,783 shares during the last quarter.

Key Stories Impacting Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q4 results beat consensus — Omada reported $0.08 EPS vs. a ($0.04) consensus and $75.85M revenue, with year-over-year revenue growth and positive adjusted EBITDA and Q4 net income, signaling improving profitability. GlobeNewswire: Q4 & Full-Year Results
• Positive Sentiment: Company set a 2026 revenue-growth target (~22%) and is expanding its care offerings (new GLP-1 and cholesterol programs), which underpin upside to recurring revenue and member monetization. Seeking Alpha: 22% Growth Target & New Programs
• Positive Sentiment: Product launch — Omada announced “GLP‑1 Flex Care,” a program that enables employer-sponsored access to GLP‑1 obesity care while limiting employer drug-cost exposure, which could broaden sales channels and employer uptake. GlobeNewswire: GLP-1 Flex Care
• Positive Sentiment: Goldman Sachs maintained a Buy rating with a $26 target, citing a profitability inflection and double-digit growth outlook — a supportive institutional endorsement. TipRanks: Goldman Sachs Note
• Neutral Sentiment: Morgan Stanley trimmed its price target slightly (from $32 to $30) but kept an Overweight rating — still implies significant upside, so the impact is muted. Benzinga: Morgan Stanley PT
• Negative Sentiment: Several firms cut price targets — Canaccord lowered its target to $22 (still Buy), BMO cut to $18 (Outperform), and Barclays reduced its target to $17 — these cuts can create downward pressure despite bullish ratings. Benzinga: Canaccord / BMO notes TickerReport AmericanBankingNews: Barclays

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.